Vertex Pharmaceuticals (VRTX) stock rose 6.2% after Morgan Stanley upgraded its rating to &#34;Overweight&#34; with a new price target of $516, up from $438. This optimism is driven by the potential of Vertex's kidney drug pipeline, specifically Pove and Inaxaplin, ahead of their Phase 3 clinical trial data release in 2026. The stock's performance also reflects broader market sentiment, including hopes for interest rate cuts.

福泰制药

<p>Vertex Pharmaceuticals (VRTX) 的股票上涨了 6.2%，因为摩根士丹利将其评级上调至 “增持”，并将目标价从 438 美元上调至 516 美元。这一乐观情绪源于 Vertex 肾脏药物管线的潜力，特别是 Pove 和 Inaxaplin，预计将在 2026 年发布其三期临床试验数据。该股票的表现也反映了更广泛的市场情绪，包括对降息的期望</p>

为什么福泰制药 (VRTX) 的股票今天上涨